Novartis is reportedly in talks with Medicines Co. about a potential buyout, although there’s no guarantee a deal will be reached.
Medicines Co. is developing an injectable drug, called inclisiran, that showed in a late-stage study that it cut bad cholesterol in half over 18 months. The drug would fit in with Novartis’ rapidly growing heart failure drug, Entresto.
Shares of Medicines Co. more than tripled this year, leaving the drugmaker with a market value of about $4.7 billion, according to Bloomberg.
Read the full article here.
More articles on pharmacy:
Drugmakers could lose $1T in sales and still be most profitable industry, analysis finds
CAR-T costs ‘not sustainable’ for hospitals, researchers say
How Walgreens, CVS see the future of pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
